MX2021005573A - Uso del compuesto cannabinoide en el tratamiento de la neurodermatitis. - Google Patents

Uso del compuesto cannabinoide en el tratamiento de la neurodermatitis.

Info

Publication number
MX2021005573A
MX2021005573A MX2021005573A MX2021005573A MX2021005573A MX 2021005573 A MX2021005573 A MX 2021005573A MX 2021005573 A MX2021005573 A MX 2021005573A MX 2021005573 A MX2021005573 A MX 2021005573A MX 2021005573 A MX2021005573 A MX 2021005573A
Authority
MX
Mexico
Prior art keywords
combination
tetrahydrocannabinovarin
cannabidivarin
cannabinoid compound
cannabidiol
Prior art date
Application number
MX2021005573A
Other languages
English (en)
Inventor
Ke Zhang
Xin Tan
Tanran Chang
Qian Jin
Original Assignee
Hanyi Bio Tech Beijing Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanyi Bio Tech Beijing Co Ltd filed Critical Hanyi Bio Tech Beijing Co Ltd
Publication of MX2021005573A publication Critical patent/MX2021005573A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención divulga el uso de un compuesto cannabinoide o sales farmacéuticamente aceptables del mismo en la preparación de una composición farmacéutica para el tratamiento de la neurodermatitis, en la que el compuesto cannabinoide puede ser uno seleccionado del grupo que consiste en tetrahidrocannabinol, cannabidiol, cannabidivarina y tetrahidrocannabinovarina o seleccionado del grupo que consiste en (1) una combinación de tetrahidrocannabinol y tetrahidrocannabinovarina; (2) una combinación de cannabidiol y cannabidivarina; (3) una combinación de tetrahidrocannabinol y cannabidivarina (4) una combinación de cannabidiol y tetrahidrocannabinovarina (5) una combinación de cannabidiol, cannabidivarina y tetrahidrocannabinovarina, (6) una combinación de tetrahidrocannabinol, cannabidivarina y tetrahidrocannabinovarina.
MX2021005573A 2018-11-12 2018-11-12 Uso del compuesto cannabinoide en el tratamiento de la neurodermatitis. MX2021005573A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2018/115075 WO2020097765A1 (zh) 2018-11-12 2018-11-12 大麻素类化合物在治疗神经性皮炎中的应用

Publications (1)

Publication Number Publication Date
MX2021005573A true MX2021005573A (es) 2021-07-02

Family

ID=70730223

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021005573A MX2021005573A (es) 2018-11-12 2018-11-12 Uso del compuesto cannabinoide en el tratamiento de la neurodermatitis.

Country Status (7)

Country Link
US (1) US20210393574A1 (es)
EP (1) EP3868373B1 (es)
JP (1) JP2022509008A (es)
AU (1) AU2018449013A1 (es)
CA (1) CA3118535C (es)
MX (1) MX2021005573A (es)
WO (1) WO2020097765A1 (es)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002222963B2 (en) 2000-07-13 2007-05-10 Oracle International Corporation Performing spreadsheet-like calculations in a database system
CH695661A5 (de) * 2001-03-06 2006-07-31 Forsch Hiscia Ver Fuer Krebsfo Pharmazeutische Zusammensetzung.
GB2414933B (en) * 2004-06-08 2009-07-15 Gw Pharma Ltd Cannabinoid compositions for the treatment of disease and/or symptoms in arthritis
HUE026929T2 (en) * 2010-10-19 2016-08-29 Parenteral A S Composition for treating inflammatory diseases comprising boswellic acids and cannabidol
US8642645B2 (en) * 2011-05-20 2014-02-04 Brooks Kelly Research, LLC. Pharmaceutical composition comprising Cannabinoids
US20170042791A1 (en) * 2015-08-11 2017-02-16 KannaInnovations LLC Topical compositions comprising hydroxy acids and cannabinoids for skin care
GB2542797A (en) * 2015-09-29 2017-04-05 Gw Pharma Ltd Use of cannabinoids in the treatment of inflammatory skin diseases
BR112019006463A2 (pt) * 2016-10-12 2019-06-25 Columbia Care Llc composição oral de canabinoides extraídos e métodos de uso da mesma
WO2018148785A1 (en) * 2017-02-15 2018-08-23 Botanix Pharmaceuticals Ltd Formulations of cannabinoids for the treatment of dermatitis and inflammatory skin diseases
CN109200046A (zh) * 2017-07-04 2019-01-15 汉义生物科技（北京）有限公司 大麻素类化合物在治疗神经性皮炎中的应用

Also Published As

Publication number Publication date
AU2018449013A1 (en) 2021-05-20
US20210393574A1 (en) 2021-12-23
EP3868373B1 (en) 2023-08-30
WO2020097765A1 (zh) 2020-05-22
CA3118535C (en) 2024-03-12
JP2022509008A (ja) 2022-01-20
CA3118535A1 (en) 2020-05-22
EP3868373A1 (en) 2021-08-25
EP3868373A4 (en) 2021-11-17

Similar Documents

Publication Publication Date Title
GEP20227406B (en) Chromane monobactam compounds for the treatment of bacterial infections
WO2018234568A3 (en) HYDROXYNORKETAMINE FOR USE IN TREATING DEPRESSION
MX2021006884A (es) Compuestos y su uso para el tratamiento de la deficiencia de alfa1-antitripsina.
WO2015160975A3 (en) Combination of a pi3k inhibitor with a bcl-2 inhibitor for use in the treatment of cancer
WO2021062231A3 (en) Cannabinoid prodrug compounds
CY1108676T1 (el) Οφθαλμικο εναιωρημα περιλαμβανον ενα οφθαλμικο φαρμακο, μια πολοξαμινη και εναν παραγοντα ρυθμισεως της τονικοτητας τυπου γλυκολης, χρηση της εν λογω συνθεσεως για την παραγωγη ενος φαρμακου για την αγωγη οφθαλμικων διαταραχων
PH12021551268A1 (en) 3,3-difluoroallylamines or salts thereof and pharmaceutical compositions comprising the same
MX2020011873A (es) Nuevos derivados de quinolina.
GEP20217266B (en) CHROMANE, ISOCHROMANE AND DIHYDROISOBENZOFURAN DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE
MX2020012800A (es) Cannabinoides y usos de los mismos.
MXPA05010160A (es) Combinacion sinergistica que comprende roflumilast y un agente anticolinergico seleccionado a partir de sales de ipratropio, oxitropio y tiotropio para el tratamiento de enfermedades respiratorias.
MX2019008338A (es) Composicion farmaceutica que contiene sulglicotido o una sal farmaceuticamente aceptable del mismo para la prevencion o tratamiento del ojo seco.
EP3845516A4 (en) NEW HIF-1alfa INHIBITOR, METHOD FOR PREPARING IT AND PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF AN ANGIOGENESIS-ASSOCIATED EYE DISEASE, CONTAINING THE SAME AS AN ACTIVE INGREDIENT
MX2021010022A (es) Composicion farmaceutica.
MX2021005573A (es) Uso del compuesto cannabinoide en el tratamiento de la neurodermatitis.
CR20210029A (es) MÉTODOS DE TRATAMIENTO DE HFpEF EMPLEANDO DAPAGLIFLOZINA Y COMPOSICIONES QUE COMPRENDEN LA MISMA
MX2021010491A (es) Tratamiento de fibromas con vitamina d y un agente tal como galato de epigalocatequina (egcg).
BR112012024346A2 (pt) agente terapêutico ou agente profilático para a doença de alzheimer
MX2021001349A (es) Un nuevo tratamiento medico para la inflamacion patologica.
WO2019070709A8 (en) Compounds for treating or preventing flavivirus infections
WO2018024888A8 (en) Compositions and the use thereof for treating or preventing rosacea
IL289943A (en) Medicinal and/or pharmaceutical compositions for insertion into a blister, preparation and uses
WO2021087127A8 (en) Cannabinoids and uses thereof
PH12020500510A1 (en) Prophylactic and/or therapeutic agent for diseases involving ido expression
LV15503A (lv) 2H-selenofēn[3,2-h]hromēni izmantošanai vēža profilaksē un ārstēšanā